書誌事項
- 公開日
- 2009-01
- DOI
-
- 10.1080/10428190802709446
- 公開者
- Informa UK Limited
この論文をさがす
説明
Human T-cell leukemia virus type I (HTLV-I) is ahuman retrovirus and an aetiologic agent of adult T-cell leukemia/lymphoma (ATL/ATLL) [1,2]. ATL/ATLL have a poor prognosis with a median survivalrate of *6 months [3]. Novel therapeutic strategiesfor ATL are required. In the current study, wefocused on mammalian target of rapamycin (mTOR)[4], a serine/threonine kinase that is a downstream
収録刊行物
-
- Leukemia & Lymphoma
-
Leukemia & Lymphoma 50 (4), 645-647, 2009-01
Informa UK Limited
